Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer

References

• Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–548. 27918777
   PubMed Web of Science ®Google Scholar
• Stewart BW, Wild C. World Cancer Report 2014 [M]. Lyon, France : International Agency for Research on Cancer, 2014:16–53.
   Google Scholar
• Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193. doi:10.3322/caac.2139528248415
   PubMed Web of Science ®Google Scholar
• Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 1999;19(3):472–484.10073946
   PubMed Web of Science ®Google Scholar
• Zhang J, Guo F, Wang L, et al. Identification of apolipoprotein C-I as a potential Wilms‘ tumor marker after excluding inflammatory factors. Int J Mol Sci. 2014;15(9):16186–16195. doi:10.3390/ijms15091618625222555
   PubMed Web of Science ®Google Scholar
• Moore LE, Brennan P, Karami S, et al. Apolipoprotein E/C1 locus variants modify renal cell carcinoma risk. Cancer Res. 2009;69(20):8001–8008. doi:10.1158/0008-5472.CAN-09-173419808960
   PubMed Web of Science ®Google Scholar
• Takano S, Yoshitomi H, Togawa A, et al. Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Ongogene. 2008;27(20):2810–2822. doi:10.1038/sj.onc.1210951
   PubMed Web of Science ®Google Scholar
• Fan Y, Shi L, Liu Q, et al. Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol Cancer. 2009;8:79. doi:10.1186/1476-4598-8-7919785722
   PubMed Web of Science ®Google Scholar
• Jong MC, van Dijk KW, Dahlmans VE, et al. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochem J. 1999;338(Pt 2):281–287.10024503
   PubMed Web of Science ®Google Scholar
• Jong MC, Dahlmans VE, van Gorp PJ, et al. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest. 1996;98(10):2259–2267. doi:10.1172/JCI1190368941642
   PubMed Web of Science ®Google Scholar
• Zhang H, Liang B, Li T, et al. Orexin A suppresses oxidized LDL induced endothelial cell inflammation via MAPK p38 and NF-kappaB signaling pathway. IUBMB Life. 2018;70(10):961–968. doi:10.1002/iub.189030207631
   PubMed Web of Science ®Google Scholar
• Li W, Zhi W, Zhao J, et al. Cinnamaldehyde protects VSMCs against ox-LDL-induced proliferation and migration through S arrest and inhibition of p38, JNK/MAPKs and NF-kappaB. Vascul Pharmacol. 2018;108:57–66. doi:10.1016/j.vph.2018.05.00529777873
   PubMed Web of Science ®Google Scholar
• Wang X, Mao R, Chen W. FSD-C10 shows therapeutic effects in suppressing oxidized low-density lipoprotein (ox-LDL)-induced human brain microvascular endothelial cells apoptosis via Rho-Associated Coiled-Coil Kinase (ROCK)/Mitogen-Activated Protein Kinase (MAPK) Signaling. Med Sci Monit. 2018;24:5509–5516. doi:10.12659/MSM.91148130088495
   PubMed Web of Science ®Google Scholar
• Wang S, Zhou H, Feng T, et al. beta-Glucan attenuates inflammatory responses in oxidized LDL-induced THP-1 cells via the p38 MAPK pathway. Nutr Metab Cardiovasc Dis. 2014;24(3):248–255. doi:10.1016/j.numecd.2013.09.01924418375
   PubMed Web of Science ®Google Scholar
• Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75(1):50–83. doi:10.1128/MMBR.00031-1021372320
   PubMed Web of Science ®Google Scholar
• Waetzig V, Herdegen T. Neurodegenerative and physiological actions of c-Jun N-terminal kinases in the mammalian brain. Neurosci Lett. 2004;361(1–3):64–67. doi:10.1016/j.neulet.2004.02.04115135894
   PubMed Web of Science ®Google Scholar
• Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911–1912. doi:10.1126/science.107268212471242
   PubMed Web of Science ®Google Scholar
• Chen Z, Cobb MH. Regulation of stress-responsive mitogen-activated protein (MAP) kinase pathways by TAO2. J Biol Chem. 2001;276(19):16070–16075. doi:10.1074/jbc.M10068120011279118
   PubMed Web of Science ®Google Scholar
• Xu K, Song X, Chen Z, et al. XRCC2 promotes colorectal cancer cell growth, regulates cell cycle progression, and apoptosis. Medicine (Baltimore). 2014;93(28):e294. doi:10.1097/MD.000000000000029425526472
   PubMed Web of Science ®Google Scholar
• Li C, Cao L, Xu C, et al. The immunohistochemical expression and potential prognostic value of HDAC6 and AR in invasive breast cancer. Hum Pathol. 2018;75:16–25. doi:10.1016/j.humpath.2017.11.01029180246
   PubMed Web of Science ®Google Scholar
• Xu K, Chen Z, Cui Y, et al. Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2/M arrest and gamma-H2AX foci formation in colorectal cancer. Onco Targets Ther. 2015;8:3047–3054. doi:10.2147/OTT.S8915426543375
   PubMed Web of Science ®Google Scholar
• Qin CJ, Song XM, Chen ZH, et al. XRCC2 as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy. Oncotarget. 2015;6(31):32193–32204. doi:10.18632/oncotarget.497526320178
   PubMedGoogle Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.050658010216199517
   PubMed Web of Science ®Google Scholar
• Subramanian A, Kuehn H, Gould J, et al. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007;23(23):3251–3253. doi:10.1093/bioinformatics/btm36917644558
   PubMed Web of Science ®Google Scholar
• Notterman DA, Alon U, Sierk AJ, et al. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 2001;61(7):3124–3130.11306497
   PubMed Web of Science ®Google Scholar
• Gaspar C, Cardoso J, Franken P, et al. Cross-species comparison of human and mouse intestinal polyps reveals conserved mechanisms in adenomatous polyposis coli (APC)-driven tumorigenesis. Am J Pathol. 2008;172(5):1363–1380. doi:10.2353/ajpath.2008.07085118403596
   PubMed Web of Science ®Google Scholar
• Skrzypczak M, Goryca K, Rubel T, et al. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One. 2010;5(10). doi:10.1371/annotation/8c585739-a354-4fc9-a7d0-d5ae26fa06ca
   PubMed Web of Science ®Google Scholar
• Kaiser S, Park YK, Franklin JL, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol. 2007;8(7):R131. doi:10.1186/gb-2007-8-5-r8117615082
   PubMed Web of Science ®Google Scholar
• Hong Y, Downey T, Eu KW, et al. A ‘metastasis-prone‘ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis. 2010;27(2):83–90. doi:10.1007/s10585-010-9305-420143136
   PubMed Web of Science ®Google Scholar
• Budinska E, Popovici V, Tejpar S, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol. 2013;231(1):63–76. doi:10.1002/path.421223836465
   PubMed Web of Science ®Google Scholar
• Gundert M, Edelmann D, Benner A, et al. Genome-wide DNA methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol classifier). Gut.  2019;68:101–110.
   Web of Science ®Google Scholar
• Bus P, Pierneef L, Bor R, et al. Apolipoprotein C-I plays a role in the pathogenesis of glomerulosclerosis. J Pathol. 2017;241(5):589–599. doi:10.1002/path.485927976371
   PubMed Web of Science ®Google Scholar
• Moore D, McNeal C, Macfarlane R. Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease. Biochem Biophys Res Commun. 2011;404(4):1034–1038.21187063
   PubMed Web of Science ®Google Scholar
• Bouillet B, Gautier T, Blache D, et al. Glycation of apolipoprotein C1 impairs its CETP inhibitory property: pathophysiological relevance in patients with type 1 and type 2 diabetes. Diabetes Care. 2014;37(4):1148–1156. doi:10.2337/dc13-146724574346
   PubMed Web of Science ®Google Scholar
• Seripa D, Bizzarro A, Pilotto A, et al. TOMM40, APOE, and APOC1 in primary progressive aphasia and frontotemporal dementia. J Alzheimers Dis. 2012;31(4):731–740. doi:10.3233/JAD-2012-12040322710912
   PubMed Web of Science ®Google Scholar
• Cohen M, Yossef R, Erez T, et al. Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. PLoS One. 2011;6(1):e14540. doi:10.1371/journal.pone.001454021267442
   PubMed Web of Science ®Google Scholar
• Ko HL, Wang YS, Fong WL, et al. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for lung cancer: A marker phase I trial. Thorac Cancer. 2014;5(6):500–508. doi:10.1111/1759-7714.1211726767044
   PubMed Web of Science ®Google Scholar
• Engwegen JY, Helgason HH, Cats A, et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol. 2006;12(10):1536–1544.16570345
   PubMed Web of Science ®Google Scholar
• Yasui W, Oue N, Ito R, et al. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci. 2004;95(5):385–392.15132764
   PubMed Web of Science ®Google Scholar
• Trougakos IP, So A, Jansen B, et al. Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 2004;64(5):1834–1842.14996747
   PubMed Web of Science ®Google Scholar
• Iacobuzio-Donahue CA, Ryu B, Hruban RH, et al. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol. 2002;160(1):91–99. doi:10.1016/S0002-9440(10)64353-211786403
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhang J, Guo F, et al. Identification of apolipoprotein C-I peptides as a potential biomarker and its biological roles in breast cancer. Med Sci Monit. 2016;22:1152–1160.27052600
   PubMed Web of Science ®Google Scholar
• Ma XL, Gao XH, Gong ZJ, et al. Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. Oncotarget. 2016;7(43):70654–70668. doi:10.18632/oncotarget.1220327683106
   PubMedGoogle Scholar
• Sol EM, Sundsten T, Bergsten P. Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells. Lipids Health Dis. 2009;8:3. doi:10.1186/1476-511X-8-4919196457
   PubMed Web of Science ®Google Scholar
• Jayakar SK, Loudig O, Brandwein-Gensler M, et al. Apolipoprotein E promotes invasion in oral squamous cell carcinoma. Am J Pathol. 2017;187(10):2259–2272. doi:10.1016/j.ajpath.2017.06.01628751006
   PubMed Web of Science ®Google Scholar
• Han HB, Gu J, Ji DB, et al. PBX3 promotes migration and invasion of colorectal cancer cells via activation of MAPK/ERK signaling pathway. World J Gastroenterol. 2014;20(48):18260–18270. doi:10.3748/wjg.v20.i48.1826025561793
   PubMed Web of Science ®Google Scholar
• Tian XQ, Guo FF, Sun DF, et al. Downregulation of ZNF278 arrests the cell cycle and decreases the proliferation of colorectal cancer cells via inhibition of the ERK/MAPK pathway. Oncol Rep. 2017;38(6):3685–3692. doi:10.3892/or.2017.603129039562
   PubMed Web of Science ®Google Scholar